Genetic features and therapeutic relevance of emergent circulating tumor DNA alterations in refractory non-colorectal gastrointestinal cancers

David Hsiehchen (), Leslie Bucheit, Dong Yang, Muhammad Shaalan Beg, Mir Lim, Sunyoung S. Lee, Pashtoon Murtaza Kasi, Ahmed O. Kaseb and Hao Zhu
Additional contact information
David Hsiehchen: University of Texas Southwestern Medical Center
Leslie Bucheit: Guardant Health Inc
Dong Yang: Guardant Health Inc
Muhammad Shaalan Beg: University of Texas Southwestern Medical Center
Mir Lim: University of Texas Southwestern Medical Center
Sunyoung S. Lee: University of Texas MD Anderson Cancer Center
Pashtoon Murtaza Kasi: Weill Cornell Medicine, Englander Institute of Precision Medicine, Meyer Cancer Center
Ahmed O. Kaseb: University of Texas MD Anderson Cancer Center
Hao Zhu: University of Texas Southwestern Medical Center

Nature Communications, 2022, vol. 13, issue 1, 1-10

Abstract: Abstract Acquired resistance to systemic treatments is inevitable in most cancers, but the genetic basis for this in many cancer types has remained elusive due to constraints in obtaining tissue specimens longitudinally. In the management of gastrointestinal cancers, molecular profiling is conventionally performed at a single time point, although serial evaluations may yield biological insights that inform treatment decisions. We characterize genetic changes in serial liquid biopsies which provide real-time snapshots of tumor genetics and heterogeneity in refractory non-colorectal gastrointestinal cancers, and determine the clinical utility of repeat circulating tumor DNA (ctDNA) testing. In a national cohort of 449 patients with pancreatic, biliary, esophagogastric, and hepatocellular cancers, resistance to conventional therapies is broadly associated with tumor evolution. Emergent ctDNA alterations only detectable at progression occurs in 63% of patients and are frequently associated with treatment actionability. Tumor mutation burden is dynamic in cancers undergoing treatment, but is not associated with time to progression. Objective tumor responses in a case series of patients receiving treatment matched to emergent alterations show that repeat liquid biopsies may have clinical benefit by expanding treatment options in advanced gastrointestinal cancers.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-35144-1 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-35144-1

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-35144-1

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().